Catalyst Wire Dossier Catalyst Wire Dossier

Ublituximab

ublituximab · TG Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

29 regulatory and trial events tracked for Ublituximab, covering 2019-06-06 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis [Phase 3]

See pricing